Compare DexCom, Inc. (DXCM) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Orion Office REIT Inc — how do they compare? DexCom, Inc. trades at $77.84 (market cap $28.06B), while Orion Office REIT Inc trades at $2.69 (market cap $151.17M). The key difference: DexCom, Inc. is far larger — about 185.6× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.01% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | ONL | |
|---|---|---|
Market Cap | $28.06B | $151.17M |
Sector | Health | Real Estate |
52-Week High | $89.53 | $3.04 |
52-Week Low | $54.84 | $1.93 |
Enterprise Value | $27.03B | $634.82M |
Dividend Yield | — | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
ONL trades at $2.66 with no recent price change, reflecting a bearish technical signal. The company reported a net loss of $139.31 million in 2025, with revenue declining to $147.65 million. Despite a high gross margin of 56.71%, negative net income and ROE highlight profitability challenges. Recent news indicates strategic reviews and portfolio repositioning, while analyst consensus is split evenly between Buy and Hold.
The outlook remains cautious due to persistent losses and high debt levels, though asset sales and refinancing efforts provide some stability. Investment opportunities exist if strategic initiatives improve cash flow, but risks include ongoing operational deficits and market volatility in the office REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
